Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04178122 · ClinicalTrials.gov registry record · NA
Million Veteran Program Return of Actionable Results
A NA study of Cardiovascular Disease, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- NA
- Development phase
- 112
- Enrollment target
- 1
- Study location
NCT04178122: Completed NA study of Cardiovascular Disease, sponsored by VA Office of Research and Development.
NCT04178122 is a NA study of Cardiovascular Disease that has completed, run by VA Office of Research and Development. The registered enrollment target is 112 participants, below the 2,697-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04178122, a NA study of Cardiovascular Disease, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- NA
- Development phase
- 112 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the Million Veteran Program- Return of Actionable Results (MVP-ROAR) Study is to develop a process to return medically actionable genetic results to living MVP participants nationwide and to determine the impact of doing so on medical management and outcomes and Veteran quality of life.
Primary Outcome
Change in LDL-C after 6 months.
Conditions Studied
Interventions
- GENETIC Result disclosure
Study Locations (1)
Massachusetts
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2020-02-27 |
| Est. Completion | 2024-09-08 |
| Phase | NA |
What the finished NCT04178122 record still lists
NCT04178122 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 2,697-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Cardiovascular Disease appearing as the primary indexed condition, and to 1 intervention - of which Result disclosure is the first listed.
NCT04178122 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04178122 about?
NCT04178122 is a clinical study titled "Million Veteran Program Return of Actionable Results". The purpose of the Million Veteran Program- Return of Actionable Results (MVP-ROAR) Study is to develop a process to return medically actionable genetic results to living MVP participants nationwide and to determine the impact of doing so on medical management and outcomes and Veteran quality of lif...
What is the current status of trial NCT04178122?
This trial is currently completed. It is a NA study. The enrollment target is 112 participants. The study started on 2020-02-27. Estimated completion is 2024-09-08.
What conditions does trial NCT04178122 study?
This clinical trial studies the following conditions: Cardiovascular Disease.
What interventions are being tested in trial NCT04178122?
The interventions under investigation include: Result disclosure (GENETIC).
Who is sponsoring clinical trial NCT04178122?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04178122 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04178122's enrollment target sits among peer trials
112 72nd of 137 higher than 65 of 137 other Cardiovascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
RECRUITING · NA
-
A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors
RECRUITING · NA
-
Gauging Outcomes of Total Milk Ingestion on Lipid and gControl
RECRUITING · NA
-
Determining the Benefits of Exercise on Cardiovascular Risk in PTSD
RECRUITING · NA
-
Century Trial, a Randomized Lifestyle Modification Study for Management of Stable Coronary Artery Disease
ACTIVE NOT RECRUITING · NA
-
Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI